Prescription ID | TCMF3368 |
Pinyin Name | Shen Qi Er Xian Pian |
Chinese Name | 参芪二仙片 |
English Name | Shen Qi Er Xian Tablets |
Function Description | 阳痿, 早泄, 遗精, 绝经前后诸症 |
Indications | Premature ejaculation disorder, Involuntary ejaculation disorder, Impotence disorder, Menopausal disorder, Menopausal and perimenopausal disorder, Sexual dysfunction, Premature ejaculation |
Disease ICD-11 Category |
SB08 [Premature ejaculation disorder (TM1), 早泄 (TM1)
]; SB09 [Involuntary ejaculation disorder (TM1), 遗精 (TM1) ]; SB0B [Impotence disorder (TM1), 阳痿 (TM1) ]; SB95 [Menopausal disorder (TM1), 绝经前后诸症 (TM1) ]; GA30 [Menopausal or certain specified perimenopausal disorders, 绝经期或某些特指的围绝经期疾患 ]; HA0Z [Sexual dysfunctions, unspecified, 性功能障碍,未特指的 ]; HA03.0Z [Male early ejaculation, unspecified, 男性早泄,未特指的 ]; |
Human Tissues Associated with Indication | Kidney |
Reference | CFDA |
Reference Book/link | http://samr.cfda.gov.cn/WS01/CL0001/ |
Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
---|---|---|---|---|
TCMH877 | Radix ginseng rubra | 红参 | TCMH877 | GBVE1679-11 |
TCMH981 | Astragalus membranaceus | 黄芪 | TCMH981 | ITSAK2981-14 |
TCMH421 | Angelica sinensis | 当归 | TCMH421 | ITSAF173-14 |
TCMH2256 | Curculigo orchioides | 仙茅 | TCMH2256 | GENG778-14 |
TCMH2507 | Epimedium brevicornum | 淫羊藿 | TCMH2507 | AY362429 |
TCMH31 | Morinda officinalis | 巴戟天 | TCMH31 | ITSAJ4459-14 |
TCMH949 | Phellodendron amurense | 黄柏 | TCMH949 | ITSAM1586-14 |
TCMH2624 | Anemarrhena asphodeloides | 知母 | TCMH2624 | GBVA3255-11, GBVU1201-13 |
Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
---|---|---|---|---|
TCMT112 | ADORA3 | Adenosine A3 receptor | GPCR | P0DMS8 |
TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
TCMT137 | CA9 | Carbonic anhydrase IX | Lyase | Q16790 |
TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
TCMT139 | CA6 | Carbonic anhydrase VI | Lyase | P23280 |
TCMT140 | CA5B | Carbonic anhydrase VB | Lyase | Q9Y2D0 |
TCMT141 | CA5A | Carbonic anhydrase VA | Lyase | P35218 |
TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
TCMT161 | HCAR2 | Hydroxycarboxylic acid receptor 2 | GPCR | Q8TDS4 |
TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
TCMT186 | MAOB | Monoamine oxidase B | Oxidoreductase | P27338 |
TCMT206 | CYP2A6 | Cytochrome P450 2A6 | Oxidoreductase | P11509 |
TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
TCMT268 | CYP2A13 | Cytochrome P450 2A13 | Oxidoreductase | Q16696 |
TCMT27 | DRD1 | Dopamine D1 receptor | GPCR | P21728 |
TCMT295 | MMP1 | Matrix metalloproteinase-1 | Hydrolase | P03956 |
TCMT296 | ADORA1 | Adenosine A1 receptor | GPCR | P30542 |
TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
TCMT298 | FABP3 | Fatty acid binding protein muscle | Hydrolase | P05413 |
TCMT306 | MMP2 | Matrix metalloproteinase-2 | Hydrolase | P08253 |
TCMT321 | MMP9 | Matrix metalloproteinase 9 | Hydrolase | P14780 |
TCMT33 | CYP3A4 | Cytochrome P450 3A4 | Oxidoreductase | P08684 |
TCMT38 | DRD2 | Dopamine D2 receptor | GPCR | P14416 |
TCMT39 | PDE5A | Phosphodiesterase 5A | Hydrolase | O76074 |
TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
TCMT597 | SLC28A3 | Solute carrier family 28 member 3 | Transporter | Q9HAS3 |
TCMT599 | UBE2N | Ubiquitin-conjugating enzyme E2 N | Transferase | P61088 |
TCMT614 | EGLN1 | Egl nine homolog 1 | Oxidoreductase | Q9GZT9 |
TCMT63 | PPARA | Peroxisome proliferator-activated receptor alpha | Nuclear receptor | Q07869 |
TCMT637 | SIRT3 | NAD-dependent deacetylase sirtuin 3 | Hydrolase | Q9NTG7 |
TCMT638 | SIRT2 | NAD-dependent deacetylase sirtuin 2 | Hydrolase | Q8IXJ6 |
TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
TCMT690 | HDAC3 | Histone deacetylase 3 | Hydrolase | O15379 |
TCMT709 | SLC28A2 | Sodium/nucleoside cotransporter 2 | Transporter | O43868 |
TCMT710 | SLC28A1 | Sodium/nucleoside cotransporter 1 | Transporter | O00337 |
TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
Target ID | Target Name |
---|---|
TCMT1176 | Streptococcus pneumoniae |
TCMT1178 | Actinomyces viscosus |
TCMT1190 | Plasmodium falciparum (isolate FcB1 / Columbia) |
TCMT1208 | Escherichia coli K12 |
TCMT1209 | Staphylococcus haemolyticus |
TCMT1212 | Verticillium dahliae |
TCMT1215 | Pseudomonas aeruginosa PAO1 |
TCMT1218 | Staphylococcus aureus |
TCMT1223 | Staphylococcus epidermidis |
TCMT1226 | Klebsiella pneumoniae |
TCMT1227 | Streptococcus |
TCMT1229 | Enterococcus faecalis |
TCMT1230 | Human herpesvirus 5 |
TCMT1232 | Pseudomonas aeruginosa |
TCMT1236 | Mycobacterium bovis |
TCMT1245 | Phytophthora cactorum |
TCMT1246 | Escherichia coli |
TCMT1251 | Candida albicans |
TCMT1253 | Penicillium chrysogenum |
TCMT1255 | Human immunodeficiency virus 1 |
TCMT1284 | Penicillium expansum |
TCMT1286 | Bacillus cereus |
TCMT1289 | Shigella dysenteriae |
TCMT1294 | Human parainfluenza virus 3 |
TCMT1305 | Salmonella enteritidis |
TCMT1318 | Human T-lymphotropic virus 1 |
TCMT1346 | Helicobacter pylori |
TCMT1349 | Helicobacter pylori SS1 |
TCMT1353 | Plasmodium yoelii |
TCMT1361 | Neisseria meningitidis |
TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
TCMT1385 | Candida shehatae |
TCMT1408 | Colletotrichum gloeosporioides |
TCMT1412 | Salmonella typhimurium |
TCMT1438 | Plasmodium falciparum |
TCMT1439 | Mycobacterium smegmatis |
TCMT1442 | Leishmania donovani |
TCMT1443 | Leishmania amazonensis |
TCMT1444 | Fusarium oxysporum |
TCMT1447 | Respiratory syncytial virus |
TCMT1448 | Enterobacter aerogenes |
TCMT1449 | Influenza A virus |
TCMT1450 | Plasmodium falciparum 3D7 |
TCMT1454 | Bacillus subtilis |
TCMT1455 | Mycobacterium tuberculosis H37Rv |
TCMT1458 | Filobasidiella neoformans |
TCMT1460 | Mycobacterium intracellulare |
TCMT1462 | Streptococcus mutans |
TCMT1463 | Mycobacterium tuberculosis |
TCMT1464 | Hepatitis B virus |
TCMT1465 | Entamoeba histolytica |
GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
---|---|---|---|
[BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 14.4797 |
[BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 13.4223 |
[BP] GO:0044281 | small molecule metabolic process | AKR1B1, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, FABP3, PDE5A, PPARA, XDH | 9.50242 |
[BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, DRD2, FABP3, PPARA | 9.17067 |
[BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, DRD2, FABP3, PPARA | 7.87558 |
[BP] GO:0006629 | lipid metabolic process | ACHE, ADORA1, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, DRD2, FABP3, FABP4, HSD17B1, PPARA | 6.75522 |
[BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 6.3671 |
[BP] GO:0019748 | secondary metabolic process | AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 6.29851 |
[BP] GO:0009056 | catabolic process | ACHE, ADORA1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP3A4, FABP3, FABP4, MAOB, MMP1, MMP2, MMP9, PDE5A, XDH | 5.31035 |
[BP] GO:0008202 | steroid metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP3A4, HSD17B1 | 4.9728 |
[BP] GO:0010817 | regulation of hormone levels | ACHE, ADORA1, AKR1B1, CYP19A1, CYP1A1, CYP1B1, CYP3A4, DRD2, HCAR2, HSD17B1 | 4.83158 |
[BP] GO:0017144 | drug metabolic process | ACHE, AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP3A4, DRD1, DRD2, MAOB | 4.69556 |
[BP] GO:0006811 | None | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, DRD1, DRD2, FABP3, PPARA | 4.61038 |
[BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, CYP3A4, HSD17B1 | 4.55447 |
[BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, CYP3A4, HSD17B1 | 4.55164 |
[BP] GO:0019369 | arachidonic acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 4.52065 |
[BP] GO:0044255 | cellular lipid metabolic process | ACHE, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, DRD2, FABP3, FABP4, PPARA | 4.26425 |
[BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1, MAOB | 4.23143 |
[BP] GO:0010035 | response to inorganic substance | AKR1B1, CA2, CYP1A1, CYP1A2, CYP1B1, DRD2, FABP4, MAOB, MMP9 | 4.16471 |
[BP] GO:0009698 | phenylpropanoid metabolic process | CYP1A1, CYP2A13, CYP2A6 | 3.96929 |
[BP] GO:0009804 | coumarin metabolic process | CYP1A1, CYP2A13, CYP2A6 | 3.96929 |
[BP] GO:0008152 | metabolic process | ACHE, ADORA1, AKR1B1, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, DRD1, DRD2, F3, FABP3, FABP4, HSD17B1, MAOB, MMP1, MMP2, MMP9, PDE5A, PPARA, XDH | 3.91838 |
[BP] GO:0065008 | regulation of biological quality | ACHE, ADORA1, AKR1B1, CA12, CA2, CA7, CYP19A1, CYP1A1, CYP1B1, CYP3A4, DRD1, DRD2, F3, FABP3, FABP4, HCAR2, HSD17B1, MAOB, PPARA, XDH | 3.91838 |
[BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, FABP3, MAOB, MMP2, MMP9, PPARA | 3.9098 |
[BP] GO:0050665 | hydrogen peroxide biosynthetic process | CYP1A1, CYP1A2, MAOB | 3.80523 |
[BP] GO:0032228 | regulation of synaptic transmission, GABAergic | ADORA1, CA2, CA7, DRD2 | 3.78762 |
[BP] GO:0055114 | oxidation-reduction process | AKR1B1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, HSD17B1, MAOB, XDH | 3.71469 |
[BP] GO:0016042 | lipid catabolic process | ADORA1, CYP19A1, CYP1A2, CYP1B1, CYP3A4, FABP3, FABP4 | 3.60559 |
[BP] GO:0010647 | positive regulation of cell communication | ADORA1, AKR1B1, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, DRD1, DRD2, F3, HCAR2, MMP9, PDE5A, XDH | 3.55458 |
[BP] GO:0023056 | positive regulation of signaling | ADORA1, AKR1B1, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, DRD1, DRD2, F3, HCAR2, MMP9, PDE5A, XDH | 3.54065 |
[BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.53687 |
[BP] GO:1901615 | organic hydroxy compound metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, CYP3A4, DRD1, DRD2, MAOB | 3.52264 |
[BP] GO:0033559 | unsaturated fatty acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 3.42056 |
[BP] GO:0097164 | None | ACHE, AKR1B1, CSNK2A1, DRD1, DRD2, MAOB | 3.41359 |
[BP] GO:0006631 | fatty acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, PPARA | 3.39493 |
[BP] GO:0001676 | long-chain fatty acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 3.37784 |
[BP] GO:0071702 | None | ADORA1, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, DRD1, DRD2, FABP3, PPARA | 3.37678 |
[BP] GO:0006584 | None | AKR1B1, DRD1, DRD2, MAOB | 3.37165 |
[BP] GO:0009712 | None | AKR1B1, DRD1, DRD2, MAOB | 3.37165 |
[BP] GO:0042738 | exogenous drug catabolic process | CYP1A2, CYP2A6, CYP3A4 | 3.34286 |
[BP] GO:0006690 | icosanoid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 3.32919 |
[BP] GO:1901361 | None | CYP19A1, CYP1A1, CYP1A2, CYP2A6, CYP3A4, MAOB, PDE5A, XDH | 3.29605 |
[BP] GO:0010038 | response to metal ion | CA2, CYP1A1, CYP1A2, DRD2, FABP4, MAOB, MMP9 | 3.24208 |
[BP] GO:0042737 | drug catabolic process | ACHE, CYP1A2, CYP2A6, CYP3A4, MAOB | 3.16505 |
[BP] GO:0006805 | xenobiotic metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP3A4 | 3.16505 |
[BP] GO:1901575 | None | ACHE, ADORA1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP3A4, FABP3, FABP4, MAOB, PDE5A, XDH | 3.13868 |
[BP] GO:0050806 | positive regulation of synaptic transmission | ADORA1, CA2, CA7, DRD1, DRD2 | 3.05005 |
[BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, CYP3A4, HSD17B1 | 2.82782 |
[BP] GO:0014070 | response to organic cyclic compound | CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, MAOB | 2.7893 |
[BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, DRD1, DRD2, FABP3, FABP4, HSD17B1, MAOB, MMP1, MMP2, PDE5A, PPARA, XDH | 2.77544 |
[BP] GO:0050805 | negative regulation of synaptic transmission | ACHE, ADORA1, DRD1, DRD2 | 2.76179 |
[BP] GO:0010033 | response to organic substance | AKR1B1, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, FABP3, FABP4, MAOB, MMP2, PPARA | 2.72934 |
[BP] GO:0009719 | response to endogenous stimulus | AKR1B1, CA2, CA9, CSNK2A1, CYP1A2, DRD1, FABP3, MAOB, MMP2, PPARA | 2.61134 |
[BP] GO:1901568 | fatty acid derivative metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 2.57104 |
[BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.55996 |
[BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.55928 |
[BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1 | 2.50717 |
[BP] GO:0022900 | electron transport chain | AKR1B1, CYP19A1, CYP1A2, MAOB, XDH | 2.50495 |
[BP] GO:0044248 | cellular catabolic process | ACHE, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP3A4, FABP3, FABP4, MAOB, PDE5A, XDH | 2.47327 |
[BP] GO:0018958 | None | AKR1B1, DRD1, DRD2, MAOB | 2.47299 |
[BP] GO:0006706 | steroid catabolic process | CYP19A1, CYP1A2, CYP3A4 | 2.4202 |
[BP] GO:0042221 | response to chemical | AKR1B1, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, DRD1, DRD2, FABP3, FABP4, MAOB, MMP2, MMP9, PPARA | 2.39179 |
[BP] GO:0050804 | modulation of chemical synaptic transmission | ACHE, ADORA1, CA2, CA7, DRD1, DRD2 | 2.35857 |
[BP] GO:0099177 | regulation of trans-synaptic signaling | ACHE, ADORA1, CA2, CA7, DRD1, DRD2 | 2.35857 |
[BP] GO:0042417 | None | DRD1, DRD2, MAOB | 2.34069 |
[BP] GO:0009611 | response to wounding | ACHE, ADORA3, CYP1A1, DRD2, PPARA | 2.33552 |
[BP] GO:0032847 | regulation of cellular pH reduction | CA2, CA7 | 2.33408 |
[BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.33408 |
[BP] GO:0009725 | response to hormone | AKR1B1, CA2, CA9, CSNK2A1, CYP1A2, FABP3, MAOB, PPARA | 2.28115 |
[BP] GO:0042743 | hydrogen peroxide metabolic process | CYP1A1, CYP1A2, MAOB | 2.28115 |
[BP] GO:0042127 | regulation of cell proliferation | ADORA1, ADORA3, AKR1B1, CSNK2A1, CYP1B1, DRD2, F3, FABP3, MMP2, MMP9, PDE5A, XDH | 2.26972 |
[BP] GO:0032787 | None | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, PPARA | 2.26494 |
[BP] GO:0001659 | None | ADORA1, DRD1, DRD2 | 2.25073 |
[BP] GO:0032879 | regulation of localization | ACHE, ADORA1, ADORA3, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, DRD1, DRD2, F3, HCAR2, MAOB, MMP9, PPARA | 2.1562 |
[BP] GO:0021853 | None | DRD1, DRD2 | 2.1562 |
[BP] GO:1904936 | None | DRD1, DRD2 | 2.1562 |
[BP] GO:0042321 | None | ADORA1, DRD2 | 2.1562 |
[BP] GO:0072593 | reactive oxygen species metabolic process | CYP1A1, CYP1A2, CYP1B1, MAOB | 2.10859 |
[BP] GO:2000021 | regulation of ion homeostasis | ADORA1, CA2, CA7, DRD1, DRD2 | 2.09325 |
[BP] GO:0006721 | terpenoid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP3A4 | 2.03523 |
[BP] GO:0021843 | None | DRD1, DRD2 | 2.01817 |
[BP] GO:0021830 | None | DRD1, DRD2 | 2.01817 |
[BP] GO:0002933 | lipid hydroxylation | CYP1A1, CYP3A4 | 2.01817 |
[BP] GO:0021826 | None | DRD1, DRD2 | 2.01817 |
[BP] GO:0016098 | monoterpenoid metabolic process | CYP1A2, CYP3A4 | 2.01817 |
[BP] GO:0042493 | response to drug | AKR1B1, CA9, CYP1A1, CYP1B1, DRD1, DRD2, FABP3, MAOB | 2.01817 |
[CC] GO:0005789 | endoplasmic reticulum membrane | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, DRD1 | 1.49485 |
[CC] GO:0031253 | None | ADORA1, CA4, CA9, DRD1, DRD2 | 1.45577 |
[CC] GO:0016323 | basolateral plasma membrane | ADORA1, CA2, CA4, CA9 | 1.35494 |
[CC] GO:0031233 | None | CA4, F3 | 1.20236 |
[CC] GO:0097730 | None | DRD1, DRD2 | 0.894186 |
[MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 20.0804 |
[MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 13.5903 |
[MF] GO:0046914 | transition metal ion binding | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, MMP1, MMP2, MMP9, PPARA, XDH | 13.4223 |
[MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 12.4495 |
[MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4 | 10.0769 |
[MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 8.66783 |
[MF] GO:0043167 | ion binding | ACHE, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, DRD1, DRD2, F3, FABP3, FABP4, HSD17B1, MAOB, MMP1, MMP2, MMP9, PDE5A, PPARA, XDH | 8.52223 |
[MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP3A4 | 8.31526 |
[MF] GO:0043169 | cation binding | ACHE, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, DRD1, DRD2, MMP1, MMP2, MMP9, PDE5A, PPARA, XDH | 6.66791 |
[MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP3A4 | 6.54614 |
[MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4 | 6.30121 |
[MF] GO:0005506 | iron ion binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, XDH | 6.29851 |
[MF] GO:0003824 | catalytic activity | ACHE, ADORA1, AKR1B1, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, F3, HSD17B1, MAOB, MMP1, MMP2, MMP9, PDE5A, XDH | 6.02254 |
[MF] GO:0008270 | zinc ion binding | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, PPARA | 5.95786 |
[MF] GO:0020037 | heme binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4 | 5.49438 |
[MF] GO:0008395 | steroid hydroxylase activity | CYP19A1, CYP1A1, CYP2A13, CYP2A6, CYP3A4 | 5.38852 |
[MF] GO:0046906 | tetrapyrrole binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4 | 5.31035 |
[MF] GO:0048037 | cofactor binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, HSD17B1, MAOB, XDH | 5.00154 |
[MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4 | 5.00062 |
[MF] GO:0046872 | metal ion binding | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, MMP1, MMP2, MMP9, PDE5A, PPARA, XDH | 4.55447 |
[MF] GO:0016491 | oxidoreductase activity | AKR1B1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP3A4, HSD17B1, MAOB, XDH | 4.50788 |
[MF] GO:0016725 | oxidoreductase activity, acting on CH or CH2 groups | CYP1A2, CYP3A4, XDH | 3.65713 |
[MF] GO:0009055 | electron transfer activity | AKR1B1, CYP19A1, CYP1A2, MAOB, XDH | 3.26155 |
[MF] GO:0008389 | None | CYP2A13, CYP2A6 | 2.98474 |
[MF] GO:0070576 | vitamin D 24-hydroxylase activity | CYP1A1, CYP3A4 | 2.55996 |
[MF] GO:0034875 | caffeine oxidase activity | CYP1A2, CYP3A4 | 2.33408 |
[MF] GO:0033695 | oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor | CYP1A2, CYP3A4 | 2.33408 |
[MF] GO:0101020 | estrogen 16-alpha-hydroxylase activity | CYP1A1, CYP3A4 | 2.1562 |
[MF] GO:0004064 | arylesterase activity | CA1, CA2 | 2.01817 |
KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
---|---|---|
Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA5B, CA5A, CA2, CA4, CA7, CA6, CA9, CA14 | 21.8959 |
Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 | 7.5186 |
Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | CYP2A6, CYP2A13, CYP1A2, CYP1A1, CYP1B1, CYP3A4 | 7.0792 |
Chemical carcinogenesis_Homo sapiens_hsa05204 | CYP2A6, CYP2A13, CYP1A2, CYP1A1, CYP1B1, CYP3A4 | 6.8959 |
Tryptophan metabolism_Homo sapiens_hsa00380 | MAOB, CYP1A2, CYP1A1, CYP1B1 | 5.0276 |
Ovarian steroidogenesis_Homo sapiens_hsa04913 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 | 4.6988 |
Retinol metabolism_Homo sapiens_hsa00830 | CYP2A6, CYP1A2, CYP1A1, CYP3A4 | 4.2967 |
Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP2A6, MAOB, CYP1A2, CYP3A4 | 4.2897 |
cAMP signaling pathway_Homo sapiens_hsa04024 | HCAR2, ADORA1, DRD1, DRD2, PPARA | 3.7433 |
PPAR signaling pathway_Homo sapiens_hsa03320 | FABP3, FABP4, MMP1, PPARA | 4.2897 |
Metabolic pathways_Homo sapiens_hsa01100 | CYP2A6, MAOB, HSD17B1, CYP1A2, CYP1A1, AKR1B1, CYP3A4, CYP19A1, XDH | 2.8851 |
Bladder cancer_Homo sapiens_hsa05219 | MMP1, MMP2, MMP9 | 3.4796 |
Drug metabolism - other enzymes_Homo sapiens_hsa00983 | CYP2A6, CYP3A4, XDH | 3.3636 |
Cocaine addiction_Homo sapiens_hsa05030 | MAOB, DRD1, DRD2 | 3.3133 |
Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | ADORA3, ADORA1, DRD1, DRD2 | 2.2169 |
Dopaminergic synapse_Homo sapiens_hsa04728 | MAOB, DRD1, DRD2 | 2.2107 |
Caffeine metabolism_Homo sapiens_hsa00232 | CYP2A6, CYP1A2, XDH | 6.1079 |
cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | ADORA3, ADORA1, PDE5A | 1.9147 |
Alcoholism_Homo sapiens_hsa05034 | MAOB, DRD1, DRD2 | 1.8514 |
Amphetamine addiction_Homo sapiens_hsa05031 | MAOB, DRD1 | 1.6874 |
Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4, ADORA1 | 1.8199 |
AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | MMP2, F3 | 1.4307 |
Estrogen signaling pathway_Homo sapiens_hsa04915 | MMP2, MMP9 | 1.4314 |
Morphine addiction_Homo sapiens_hsa05032 | ADORA1, DRD1 | 1.4847 |
Gap junction_Homo sapiens_hsa04540 | DRD1, DRD2 | 1.4955 |
Bile secretion_Homo sapiens_hsa04976 | CA2, CYP3A4 | 1.6572 |
Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2, CYP3A4 | 2.2735 |
Pathways in cancer_Homo sapiens_hsa05200 | MMP1, MMP2, MMP9 | 1.1214 |
Sphingolipid signaling pathway_Homo sapiens_hsa04071 | ADORA3, ADORA1 | 1.3195 |
Leukocyte transendothelial migration_Homo sapiens_hsa04670 | MMP2, MMP9 | 1.3195 |
Parkinson's disease_Homo sapiens_hsa05012 | DRD1, DRD2 | 1.1976 |
Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.4496 |
Proteoglycans in cancer_Homo sapiens_hsa05205 | MMP2, MMP9 | 0.9952 |
Purine metabolism_Homo sapiens_hsa00230 | PDE5A, XDH | 1.0672 |
MicroRNAs in cancer_Homo sapiens_hsa05206 | CYP1B1, MMP9 | 0.7857 |
Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.7298 |
GnRH signaling pathway_Homo sapiens_hsa04912 | MMP2 | 0.6906 |
Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.6906 |
Adherens junction_Homo sapiens_hsa04520 | CSNK2A1 | 0.7298 |
Cholinergic synapse_Homo sapiens_hsa04725 | ACHE | 0.6661 |
Adipocytokine signaling pathway_Homo sapiens_hsa04920 | PPARA | 0.7345 |
Glucagon signaling pathway_Homo sapiens_hsa04922 | PPARA | 0.678 |
TNF signaling pathway_Homo sapiens_hsa04668 | MMP9 | 0.6661 |
Insulin resistance_Homo sapiens_hsa04931 | PPARA | 0.6661 |
Rheumatoid arthritis_Homo sapiens_hsa05323 | MMP1 | 0.6906 |
Renin secretion_Homo sapiens_hsa04924 | ADORA1 | 0.7617 |
Complement and coagulation cascades_Homo sapiens_hsa04610 | F3 | 0.7122 |
NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1 | 0.6906 |
Measles_Homo sapiens_hsa05162 | CSNK2A1 | 0.6045 |
Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.6906 |
Hepatitis C_Homo sapiens_hsa05160 | PPARA | 0.6062 |
Peroxisome_Homo sapiens_hsa04146 | XDH | 0.7007 |
Hepatitis B_Homo sapiens_hsa05161 | MMP9 | 0.5972 |
Serotonergic synapse_Homo sapiens_hsa04726 | MAOB | 0.6661 |
Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B1 | 0.7857 |
Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1 | 0.6014 |
Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.6906 |
Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | PPARA | 0.5909 |
Calcium signaling pathway_Homo sapiens_hsa04020 | DRD1 | 0.5378 |
Tight junction_Homo sapiens_hsa04530 | CSNK2A1 | 0.6028 |
Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1 | 0.5078 |
Rap1 signaling pathway_Homo sapiens_hsa04015 | DRD2 | 0.4981 |
Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | MMP9 | 0.5378 |
Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.5337 |
Arginine and proline metabolism_Homo sapiens_hsa00330 | MAOB | 0.8345 |
Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | MAOB | 0.9172 |
Galactose metabolism_Homo sapiens_hsa00052 | AKR1B1 | 0.9952 |
Tyrosine metabolism_Homo sapiens_hsa00350 | MAOB | 0.9523 |
Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B1 | 0.9512 |
Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B1 | 0.9792 |
Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 1.0162 |
Histidine metabolism_Homo sapiens_hsa00340 | MAOB | 1.054 |
Phenylalanine metabolism_Homo sapiens_hsa00360 | MAOB | 1.1622 |